Topadur Pharma AG
PrivateLast Round
Series C
Extension
Oct 1, 2024
Est. Valuation
$47.38M
Total Funding Raised
$25.75M
Company Overview
Topadur Pharma AG is a clinical-stage biopharmaceutical company that develops dual-acting small-molecule therapies to restore microcirculation and promote tissue regeneration for age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Topadur Pharma AG Comparables
Compare Topadur Pharma AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aurealis Therapeutics | 79% | |
| ElkosRx, LLC | 78% | |
| Ilya Pharma | 73% |
Topadur Pharma AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Oct 1, 2024 | ||||
| Strategic | Jun 6, 2024 | ||||
| Grant | Jan 5, 2024 | ||||
| Grant | Dec 20, 2023 | ||||
| Grant | Jun 7, 2022 | ||||
Convertible Debt | Oct 1, 2020 |
Key People
Founding team and executive leadership
Topadur Pharma AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CTI Life Sciences Fund | Grant |
| Eurostars SME programme | Grant |
| Korea Institute for Advancement of Technology | Grant |
| Innosuisse | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2025
Grew 33% QoQ, from 12 to 16 employees.
- May 1, 2025
Monthly visitors grew 119% MoM.
Topadur Pharma AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access